Novartis Global Pipeline

Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development.

Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.

For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2016.

Please note: the Novartis Pipeline data is updated quarterly.

Displaying 51 - 60 of 68 result(s)
New Indication

Promacta®/Revolade®

eltrombopag

Severe aplastic anemia 1st line

Oncology

Phase III

2018

Thrombopoietin receptor agonist

New Molecule

QAW039

fevipiprant

Asthma

Respiratory

Phase III

2019

CRTH2 antagonist

New Molecule

QBW251

Chronic obstructive pulmonary disease

Respiratory

Phase II

>=2021

CFTR potentiator

New Molecule

QGE031

ligelizumab

Chronic spontaneous urticaria / chronic idipathic urticaria

Immunology and dermatology

Phase II

2020

High-affinity anti-IgE monoclonal antibody

New Indication

QMF149

indacaterol, mometasone furoate (in fixed-dose combination)

Asthma

Respiratory

Phase III

2019

Long-acting beta2-agonist and inhaled corticosteroid

New Indication

QVM149

indacaterol, mometasone furoate (in fixed-dose combination)

Asthma

Respiratory

Phase III

2019

Long-acting beta2-agonist, long-acting muscarinic antagonist and inhaled corticosteroid

New Indication

RTH258

brolucizumab

Diabetic macular edema

Ophthalmology

Phase III

2020

Anti-vascular endothelial growth factor (VEGF) single-chain antibody fragment

New Molecule

RTH258

brolucizumab

Neovascular age-related macular degeneration

Ophthalmology

Phase III

2018

Anti-vascular endothelial growth factor (VEGF) single-chain antibody fragment

New Indication

Rydapt

midostaurin

Acute myeloid leukemia (FLT3 wild type)

Oncology

Phase III

>=2021

Signal transduction inhibitor

New Molecule

SEG101

crizanlizumab

Sickle cell disease

Oncology

Phase III

2018

P-selectin inhibitor

Pages

Legend

Combination abbreviations:
fulv fulvestrant
tmx tamoxifen
gsn goserelin
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar® (dabrafenib)
Mek Mekinist® (trametinib)
a EU filing, approved in US.
b US filing, approved in EU.
c US filing, submitted in EU.
d Lubris LLC transaction announced in April 2017.
e Conatus transaction for exclusive global license for emricasan announced in May 2017.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.